These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 23931567)

  • 21. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.
    Kimura H; Kasahara K; Sekijima M; Tamura T; Nishio K
    Lung Cancer; 2005 Dec; 50(3):393-9. PubMed ID: 16153743
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection and prevention of cardiac complications of cancer chemotherapy.
    Monsuez JJ
    Arch Cardiovasc Dis; 2012 Nov; 105(11):593-604. PubMed ID: 23177488
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Preventing the cardiotoxic effects of anthracyclins. From basic concepts to clinical data].
    Delemasure S; Vergely C; Zeller M; Cottin Y; Rochette L
    Ann Cardiol Angeiol (Paris); 2006 Apr; 55(2):104-12. PubMed ID: 16708994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells.
    Spector NL; Yarden Y; Smith B; Lyass L; Trusk P; Pry K; Hill JE; Xia W; Seger R; Bacus SS
    Proc Natl Acad Sci U S A; 2007 Jun; 104(25):10607-12. PubMed ID: 17556544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Winning the battle, but losing the war: mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity.
    Glass CK; Mitchell RN
    Cardiovasc Pathol; 2017; 30():55-63. PubMed ID: 28759820
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiotoxicity of tyrosine-kinase-targeting drugs.
    Garcia-Alvarez A; Garcia-Albeniz X; Esteve J; Rovira M; Bosch X
    Cardiovasc Hematol Agents Med Chem; 2010 Jan; 8(1):11-21. PubMed ID: 20210773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapy Insight: anthracyclines and trastuzumab--the optimal management of cardiotoxic side effects.
    Popat S; Smith IE
    Nat Clin Pract Oncol; 2008 Jun; 5(6):324-35. PubMed ID: 18364726
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiotoxicity associated with targeting kinase pathways in cancer.
    Mellor HR; Bell AR; Valentin JP; Roberts RR
    Toxicol Sci; 2011 Mar; 120(1):14-32. PubMed ID: 21177772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac toxicity of targeted therapies used in the treatment for solid tumours: a review.
    Svoboda M; Poprach A; Dobes S; Kiss I; Vyzula R
    Cardiovasc Toxicol; 2012 Sep; 12(3):191-207. PubMed ID: 22528816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis of cardiotoxicity induced by anthracyclines.
    Elliott P
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S2-7. PubMed ID: 16781283
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tyrosine kinase and phosphatase regulation of slow delayed-rectifier K+ current in guinea-pig ventricular myocytes.
    Missan S; Linsdell P; McDonald TF
    J Physiol; 2006 Jun; 573(Pt 2):469-82. PubMed ID: 16581870
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy.
    Raschi E; Vasina V; Ursino MG; Boriani G; Martoni A; De Ponti F
    Pharmacol Ther; 2010 Feb; 125(2):196-218. PubMed ID: 19874849
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metastatic renal cell carcinoma to heart: cardiac surgery versus cardiotoxicity of kinase inhibitors.
    Koniari I; Apostolakis E; Baikoussis NG
    Interact Cardiovasc Thorac Surg; 2010 Dec; 11(6):816. PubMed ID: 21097460
    [No Abstract]   [Full Text] [Related]  

  • 34. Angiotensin II activates Stat5 through Jak2 kinase in cardiac myocytes.
    McWhinney CD; Dostal D; Baker K
    J Mol Cell Cardiol; 1998 Apr; 30(4):751-61. PubMed ID: 9602424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insensitivity of cardiac delayed-rectifier I(Kr) to tyrosine phosphorylation inhibitors and stimulators.
    Missan S; Zhabyeyev P; Linsdell P; McDonald TF
    Br J Pharmacol; 2006 Jul; 148(5):724-31. PubMed ID: 16715119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Activation of extracellular signal-regulated kinase during silibinin-protected, isoproterenol-induced apoptosis in rat cardiac myocytes is tyrosine kinase pathway-mediated and protein kinase C-dependent.
    Zhou B; Wu LJ; Tashiro S; Onodera S; Uchiumi F; Ikejima T
    Acta Pharmacol Sin; 2007 Jun; 28(6):803-10. PubMed ID: 17506939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anthracycline-induced cardiotoxicity in adult hematologic malignancies.
    Johnson SA
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S22-7. PubMed ID: 16781286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiotoxicity due to cancer therapy.
    Khakoo AY; Liu PP; Force T; Lopez-Berestein G; Jones LW; Schneider J; Hill J
    Tex Heart Inst J; 2011; 38(3):253-6. PubMed ID: 21720463
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tyrosine kinase inhibitors and gut toxicity: a new era in supportive care.
    Keefe D; Anthony L
    Curr Opin Support Palliat Care; 2008 Mar; 2(1):19-21. PubMed ID: 18685389
    [No Abstract]   [Full Text] [Related]  

  • 40. Anticancer agents and cardiotoxicity.
    Ng R; Better N; Green MD
    Semin Oncol; 2006 Feb; 33(1):2-14. PubMed ID: 16473642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.